Navigation Links
Vaccination reduces the risk of unvaccinated badger cubs testing tuberculosis positive

New evidence from a four-year field study has shown that BCG vaccination reduces the risk of tuberculosis infection in unvaccinated badger cubs in vaccinated groups, as well as in badgers that received the vaccine.

The research, published today in the journal PLOS ONE provides the strongest evidence to date that unvaccinated badger cubs can be indirectly protected from TB infection when some of the badgers in their social group are vaccinated. By studying rates of new cases of TB in cubs in vaccinated social groups, researchers have shown that the risk of non-vaccinated cubs testing positive was reduced by almost 80 per cent when more than a third of badgers in their group had been vaccinated.

The results come from a controlled clinical field trial of badger vaccination, conducted by the Animal Health and Veterinary Laboratories Agency (AHVLA) and the Food and Environment Research Agency (Fera), in an area in Gloucestershire where TB is highly prevalent in the badger population.

Dr Steve Carter of Fera and lead author of the latest research said: "One concern about the effectiveness of badger vaccination is that new-born cubs might acquire TB before they first emerge above ground. As the vaccine is not expected to benefit infected individuals it has been suggested that by the time cubs emerge and are available for vaccination they might have already been exposed to TB. Therefore, vaccination for them may be too late. This study indicates that vaccination of badgers above ground can indirectly protect unvaccinated cubs before they emerge from the sett".

The latest analyses were conducted by a team of scientists at Fera, AHVLA and the Universities of Newcastle and Strathclyde.

Professor Robbie McDonald, an author of the paper and now at the University of Exeter said: "This striking result in cubs shows a protective effect at the social group level and is important evidence that vaccination not only has a direct benefit to vaccinated badgers, but can also reduce the infectivity of TB within a badger social group that has been vaccinated."

But he cautioned: "Although this is an encouraging development, the costs and benefits of vaccinating badgers for controlling disease in cattle are not yet well understood".

"This means that it is a hard choice for farmers to make without further information and trials of how it would work in practice. The current Badger Vaccine Deployment Project in Gloucestershire and experience in the Welsh Government's badger vaccine project will help deliver this experience and knowledge."


Contact: Louise Vennells
University of Exeter

Related biology technology :

1. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
2. R&D/Leverages New Opti-Sim Virtual Prototyping Tool Saves Time and Money for PET Packaging Industry -- and Reduces Waste
3. Computer vision reduces risk in clinical trials
4. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. LABS, Inc. Earns AABB Accreditation for Donor Testing
7. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
8. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
9. HPV Testing for Cervical Cancer Risk Patients set to Increase
10. Premier Research Expands Salt Lake City and Phoenix Testing Facilities Adding 50% Capacity
11. Arsenic Testing Proves Organic Baby Formula Safe
Post Your Comments:
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):